Introduction
USES OF MERIHIST TABLET
- Metastatic melanoma
- Non-small cell lung cancer
Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection. Also Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.
Warning & Precautions
Pregnancy & Breast Feeding
- Merihist 500mg/25mg/5mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
- Information regarding the use of Merihist 500mg/25mg/5mg Tablet during breastfeeding is not available. Please consult your doctor.
Driving & Using Machines
- Merihist 500mg/25mg/5mg Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
How to Use
- Treatment with trametinib should only be initiated and supervised by a physician experienced in the administration of anti-cancer medicinal products. Before taking trametinib, patients must have confirmation of BRAF V600 mutation using a validated test.
- Take this medicine in the dose and duration as advised by your doctor.
- Swallow it as a whole.
- Do not chew, crush or break it.
- Merihist 500mg/25mg/5mg Tablet should be taken without food.
Side Effects
Like all medicines, this medicine can cause side effects, although not everybody gets them
Common
- Nausea
- Dryness in mouth
- Dizziness
- Fatigue
- Palpitations
- High blood pressure
- Insomnia (difficulty in sleeping)
- Allergic reaction
- Sleepiness
More Information
- New malignancies, cutaneous and non-cutaneous, can occur when trametinib is used in combination with dabrafenib.
- New primary melanoma was reported in patients receiving trametinib in combination with dabrafenib.
- Based on its mechanism of action, dabrafenib may increase the risk of non-cutaneous malignancies when RAS mutations are present.
- Haemorrhagic events, including major haemorrhagic events and fatal haemorrhages, occurred in patients taking trametinib as monotherapy and in combination with dabrafenib in the unresectable or metastatic melanoma.
Disclaimer:The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.
Reviews
There are no reviews yet.